Jeffrey L. Quillen

Co-Chair, Life Sciences Industry Group
Jeffrey Quillen’s varied business law practice focuses on companies involved with advanced technology applications. He serves as outside general counsel to a number of emerging biotechnology, software and information technology companies.

For these and other clients he negotiates and drafts agreements regarding intellectual property rights, including patent license agreements with major research universities and collaboration agreements with pharmaceutical companies.

On the financing side, Jeffrey represents venture capital funds and emerging companies in venture capital financing transactions, including private placements of convertible preferred stock and subordinated debt.

He also represents buyers and sellers in mergers and acquisitions, involving public and private companies. His work in this area includes helping foreign companies to acquire U.S. companies and organize international operations.


  • Duke University School of Law, J.D., 1991
  • Colgate University, B.A., 1988

Bar and Court Admissions

  • District of Columbia
  • Massachusetts
  • Florida


  • MDxHealth SA (Nasdaq/Euronext: MDXH), a foreign private issuer, in its acquisition of the OncoType DX Genomic Prostate Score business from Exact Sciences Corporation (Nasdaq: EXAS) for cash and equity consideration of up to $100 million, including a multi-year earn-out arrangement
  • RedShift BioAnalytics Inc., a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, in closing its $20 million Series E Preferred Stock financing
  • H.I.G. BioHealth Partners and Accelmed Partners as new investors and co-leads in the $52 million upsized Series B financing of digital therapeutics company Click Therapeutics, Inc. (“Click”)
  • BigVisible Solutions, Inc. in the sale by its shareholders of the business to SolutionsIQ for an undisclosable amount
  • Pervasis Therapeutics in connection with a sale of substantially all of Pervasis’ assets to a subsidiary of Shire plc
  • Zosano Pharma Corporation (Nasdaq: ZSAN) in its initial public offering of 4,500,000 shares of its common stock at a price of $11.00 per share
  • Rinovum Women’s Health, a privately-held, U.S.-based women’s health company, in its Series C funding
  • Selecta Biosciences, Inc., a biopharmaceutical company founded by Dr. Omid Farokhzad and Professors Robert Langer and Ulrich von Andrian, in various equity financings totaling over $50 million, including most recently a $10 million extension of Series D financing
  • NeoGraft Technologies, a development-stage medical device company focused on coronary artery disease, in its $11 million Series C financing
  • scPharmaceuticals, Inc., a biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, in its $16 million Series A venture financing
  • ArthroMeda, Inc., a developer of medical devices designed to improve surgical outcomes for patients undergoing joint replacement procedures, in its Series B financing
  • Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of drugs to treat cancer and other diseases, on numerous financings, including a $16 million Series B financing
  • Zosano Pharma Corporation (Nasdaq: ZSAN), a California-based, biotechnology company that is a pioneer in the transdermal drug delivery field, in the negotiation of an agreement with Novo Nordisk A/S to develop a new transdermal presentation of semaglutide
  • Zosano Pharma Corporation (Nasdaq: ZSAN) in its exclusive licensing agreement with Eli Lilly and Company to develop ZP-PTH -- Zosano’s proprietary formulation of parathyroid hormone 1-34 (PTH) -- using Zosano’s microneedle patch system for the treatment of osteoporosis patients
  • Translational Therapeutics Inc. as it entered into a strategic licensing agreement with Clavis Pharma ASA of Norway regarding the development and commercialization of a thyroid cancer treatment

Honors & Involvement Overview

  • Chambers USA, Recognized Practitioner for Private Equity: Venture Capital Investment (2018-2022)
  • Listed in Best Lawyers in America® - Venture Capital Law (2007-2023 Editions)
  • Listed in Best Lawyers in Massachusetts® - Venture Capital Law (2012-2017 Editions)
  • Listed in Boston's Best Lawyers® - Venture Capital Law (2008 & 2011 Editions)
  • Endorsed by PLCWhich Lawyer? for Venture Capital and Life Sciences: Commercial and Partnering (2007-2012 Editions)
  • Listed in The Legal 500 US Volume 1 (Corporate & Finance) (2006)
  • Listed in Super Lawyers - Massachusetts Rising Stars 2005 - Securities, Corporate Finance & IP
  • Boston Bar Association, Member
  • Judge, MassChallenge Venture Funds Competition
  • Judge, Harvard Business School New Venture Competition
  • Peer Reviewer for the Massachusetts Life Sciences Center Accelerator Loan Program

Speaking Engagements

  • "Trends in Corporate VC Investment," BioPharm America (September 2022)
  • “Early Stage Financing: What Does It Take To Be One Step Ahead?,” BioPharm America (September 2019)
  • “How Pharma and VC Collaborations are Changing the Industry,” BioPharm America (September 2018)
  • “Alternative Financing and Venture Philanthropy,” BioPharm America (September 2017)
  • “C-Suite: Life in Public,” BioPharm America (September 2016)
  • “Creating a Clinical-Stage Startup by In-licensing Assets,” BioPharm America (September 2015)
  • "A Quick Spin Through Spin-Offs," NYSE Life Sciences Industry Peer Exchange (April 2015)
  • “Large Series A Financings Deconstructed,” BioPharm America (September 2014)
  • “From Discovery to Early Stage Drug Development: At the Intersection of Academia, Biotech and Pharm,” BioPharma America (September 2013)
  • “Creating Value with Limited Liability Companies and Asset-Centric Investing,” BIO International Convention (April 2013)
  • “New Financing Models for Creative Exit Strategies,” BioPharm America (September 2012)
  • JOBS Act Webinar, BIO (September 2012)